Australia’s drug regulator issues mental health warning for weight-loss drugs including Ozempic
TGA issues a separate warning for Mounjaro about risk of reduced effectiveness of contraception
Get our breaking news email, free app or daily news podcast
The medicines regulator has added two new safety warnings about mental health and contraception for people taking high-profile diabetes and weight loss drugs.
The Therapeutic Goods Administration (TGA) says that because suicidal behaviour and ideation have been reported with these relatively new GLP-1 receptor agonists, doctors should “monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviours, and/or any unusual changes in mood or behaviour”.